Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Bladder Cancer

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 13 articles: HTML format

Single Articles

April 2023
1. CHUNG R, McKiernan J, Arpaia N, Marabelle A, et al
   Neo-Adjuvant immunotherapies: Bladder cancer as a platform for drug development targeting mucosal immunity.
   Eur J Cancer. 2023;187:58-64.
   PubMed     Abstract available
   
   
   November 2022
2. MEYNARD L, Dinart D, Delaunay B, Flechon A, et al
   Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.
   Eur J Cancer. 2022;175:43-53.
   PubMed     Abstract available
   
   
   October 2022
3. YOON S, Shin SJ, Kim HC, Kim YS, et al
   Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failure.
   Eur J Cancer. 2022;174:81-89.
   PubMed     Abstract available
   
   
   June 2022
4. LIU Z, Jin K, Zeng H, Shao F, et al
   B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer.
   Eur J Cancer. 2022;171:133-142.
   PubMed     Abstract available
   
   
   May 2022
5. KLUMPER N, Sikic D, Saal J, Buttner T, et al
   C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.
   Eur J Cancer. 2022;167:13-22.
   PubMed     Abstract available
   
   
   March 2022
6. SONPAVDE GP, Sternberg CN, Loriot Y, Marabelle A, et al
   Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.
   Eur J Cancer. 2022;163:55-65.
   PubMed     Abstract available
   
   
   November 2021
7. SEETHAPATHY H, Street S, Strohbehn I, Lee M, et al
   Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors.
   Eur J Cancer. 2021;157:50-58.
   PubMed     Abstract available
   
   
   July 2021
8. MORI K, Pradere B, Moschini M, Mostafaei H, et al
   First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
   Eur J Cancer. 2021;151:35-48.
   PubMed     Abstract available
   
   
   
9. BOUDIN L, Patient M, Romeo E, Blade JS, et al
   Lurbinectedin for metastatic small-cell bladder carcinoma.
   Eur J Cancer. 2021;151:1-2.
   PubMed    
   
   
   May 2021
10. ROUANNE M, Arpaia N, Marabelle A
    CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer.
    Eur J Cancer. 2021 May 7. pii: S0959-8049(21)00222.
    PubMed    
    
    
    March 2021
11. GROENEVELD CS, Fontugne J, Cabel L, Bernard-Pierrot I, et al
    Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
    Eur J Cancer. 2021;148:181-189.
    PubMed     Abstract available
    
    
    
12. BAART VM, van der Horst G, Deken MM, Bhairosingh SS, et al
    A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resection and surveillance of urothelial cell carcinoma.
    Eur J Cancer. 2021;146:11-20.
    PubMed     Abstract available
    
    
    May 2020
13. MATSUMOTO S, Kijima T, Matsuoka Y, Yamamoto M, et al
    A case of recurrent thrombocytopenia involving divergent immune-related mechanisms associated with pembrolizumab.
    Eur J Cancer. 2020;131:104-107.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.